Skip to main content

2024 Annual Meeting Long Course: Sign-out of Medical Liver Disease and Liver Tumor Specimens in the Molecular Era: Emerging Possibilities



Original release date:
May 22, 2024
Access to this course expires on:  March 27, 2027 at 11:59 PM Pacific Time
CME 4.5

Course Description
This course will cover a variety of hepatic neoplasms and medical liver diseases where there are opportunities for ancillary molecular testing to produce refinement of the diagnosis and provide clinically relevant prognostic information. For each of the topics addressed, the most up to date morphologic features and criteria used for diagnosis will first be reviewed, and then the potential for additional molecular testing will be covered. Resources regarding the availability and technical requirements for molecular testing will also be discussed. The potential of selected exciting emerging technologies to have clinical impact in the near term future will also be included.

Target Audience
Practicing academic and community pathologists, and pathologists-in-training

Learning Objectives
Upon completion of this educational activity, learners will be able to:
  • Recognize the utility of germline testing to identify disease risk alleles for selected medical liver diseases
  • Identify circumstances where molecular testing of benign and malignant liver tumors can be helpful in patient management decisions
  • Understand the circumstances where molecular testing can supplement immunohistochemistry in the identification of the origin of hepatic metastatic tumors

Continuing Medical Education
The United States and Canadian Academy of Pathology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The United States and Canadian Academy of Pathology designates this enduring material for a maximum of 4.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures
The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to USCAP and to learners any financial relationship(s) that have occurred within the last 24 months with any commercial interest(s) whose products or services are related to the CME content. USCAP has reviewed all disclosures and mitigated all identified conflicts of interest, as applicable.

The following faculty reported no relevant financial relationships: John A. Hart, MD, Daniella Allende, MD, Rondell P. Graham, MBBS, Romil Saxena, MD, MBBS, FRCPath, Lei Zhao, MD, PhD, Health L. Stevenson-Lerner, MD, PhD, Valerie Paradis, MD, PhD, Julien Calderaro, MD, PhD

The following Education Committee members reported financial relationships:
Kimberly Allison: Advisory Board Member, Mammotome
Marilyn Bui: Consultant, Aiforia, AstraZeneca, ContextVision, Merck, Visiopharm; Speaker, Gather-Ed, Osler Review, Roche Ventana; Other, Caris
Jennifer Gordetsky: Consultant, Jansen
Tamara Lotan: Grant or Research Support, AIRAMatrix, DeepBio, Myriad Genetics
Charles Quick: Consultant, Myriad Genetics
David Schaeffer: Consultant, Alimentiv Inc, Astellas, NEED Inc; Speaker, Diaceutics; Grant or Research Support, Bayer

The following Education Committee members reported no relevant financial relationships: Adebowale J. Adeniran, Phyu P. Aung, Justin A. Bishop, Laura C. Collins, Carla L. Ellis, Sarah E. Gibson, Kristin C. Jensen, Melinda J. Lerwill, Chieh-Yu Lin, Maria Beatriz S. Lopes, Terri Mason, Nicole C. Panarelli, Carlos Parra-Herran, Ilan Weinreb, Maria Westerhoff, Rhonda K. Yantiss, Josh A. Zeitlin

USCAP staff associated with the development of content for this activity reported no relevant financial relationships.

To earn CME credit, all learners must complete the evaluation. Learners can now self-submit CME on all earned certificates. View and print your certificates by clicking here.

USCAP members receive a discount on all e-Learning courses. Not A Member? Click Here to sign up today.